763 related articles for article (PubMed ID: 31454267)
21. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
Perl AE; Larson RA; Podoltsev NA; Strickland S; Wang ES; Atallah E; Schiller GJ; Martinelli G; Neubauer A; Sierra J; Montesinos P; Recher C; Yoon SS; Maeda Y; Hosono N; Onozawa M; Kato T; Kim HJ; Hasabou N; Nuthethi R; Tiu R; Levis MJ
Transplant Cell Ther; 2023 Apr; 29(4):265.e1-265.e10. PubMed ID: 36526260
[TBL] [Abstract][Full Text] [Related]
22. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
Numan Y; Abdel Rahman Z; Grenet J; Boisclair S; Bewersdorf JP; Collins C; Barth D; Fraga M; Bixby DL; Zeidan AM; Yilmaz M; Desai P; Mannis G; Deutsch YE; Abaza Y; Dinner S; Frankfurt O; Litzow M; Al-Kali A; Foran JM; Sproat LZ; Jovanovic B; Daver N; Perl AE; Altman JK
Am J Hematol; 2022 Mar; 97(3):322-328. PubMed ID: 34981560
[TBL] [Abstract][Full Text] [Related]
23. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
Ando T; Sano H; Yokoo M; Kusaba K; Kidoguchi K; Yamaguchi K; Katsuya H; Yoshihara S; Kubota Y; Kojima K; Kimura S
Int J Hematol; 2020 Aug; 112(2):249-253. PubMed ID: 32185622
[TBL] [Abstract][Full Text] [Related]
24. [Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].
Fukuoka K; Tsumura Y; Noguchi J; Sugawa M; Takaki T; Hiraki T; Inoue K; Mitani Y; Tomita O; Oshima K; Yanagi M; Isobe K; Mori M; Arakawa Y; Koh K
Rinsho Ketsueki; 2020; 61(4):322-326. PubMed ID: 32378574
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Perl AE; Hosono N; Montesinos P; Podoltsev N; Martinelli G; Panoskaltsis N; Recher C; Smith CC; Levis MJ; Strickland S; Röllig C; Groß-Langenhoff M; Chou WC; Lee JH; Yokoyama H; Hasabou N; Lu Q; Tiu RV; Altman JK
Blood Cancer J; 2022 May; 12(5):84. PubMed ID: 35637252
[TBL] [Abstract][Full Text] [Related]
26. Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
Arrigo G; D'Ardìa S; Audisio E; Cerrano M; Freilone R; Giai V; Secreto C; Urbino I; Frairia C
Acta Haematol; 2022; 145(5):566-570. PubMed ID: 35580565
[TBL] [Abstract][Full Text] [Related]
27. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Antar AI; Otrock ZK; Jabbour E; Mohty M; Bazarbachi A
Leukemia; 2020 Mar; 34(3):682-696. PubMed ID: 31919472
[TBL] [Abstract][Full Text] [Related]
28. Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.
Hosono N; Yokoyama H; Aotsuka N; Ando K; Iida H; Ishikawa T; Usuki K; Onozawa M; Kizaki M; Kubo K; Kuroda J; Kobayashi Y; Shimizu T; Chiba S; Nara M; Hata T; Hidaka M; Fujiwara SI; Maeda Y; Morita Y; Kusano M; Lu Q; Miyawaki S; Berrak E; Hasabou N; Naoe T
Int J Clin Oncol; 2021 Nov; 26(11):2131-2141. PubMed ID: 34363558
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.
Kida M; Kuroda Y; Kido M; Chishaki R; Kuraoka K; Ito T
Int J Hematol; 2020 Aug; 112(2):243-248. PubMed ID: 32170661
[TBL] [Abstract][Full Text] [Related]
30. FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
Hogan FL; Williams V; Knapper S
Curr Cancer Drug Targets; 2020; 20(7):513-531. PubMed ID: 32418523
[TBL] [Abstract][Full Text] [Related]
31. A novel approach for relapsed/refractory FLT3
Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
[TBL] [Abstract][Full Text] [Related]
32. A review of FLT3 inhibitors in acute myeloid leukemia.
Zhao JC; Agarwal S; Ahmad H; Amin K; Bewersdorf JP; Zeidan AM
Blood Rev; 2022 Mar; 52():100905. PubMed ID: 34774343
[TBL] [Abstract][Full Text] [Related]
33. Gilteritinib: potent targeting of FLT3 mutations in AML.
Levis M; Perl AE
Blood Adv; 2020 Mar; 4(6):1178-1191. PubMed ID: 32208491
[TBL] [Abstract][Full Text] [Related]
34. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
Lee JK; Chatterjee A; Scarpa M; Bailey CM; Niyongere S; Singh P; Mustafa Ali MK; Kapoor S; Wang Y; Silvestri G; Baer MR
Cancer Res Commun; 2024 Feb; 4(2):431-445. PubMed ID: 38284896
[TBL] [Abstract][Full Text] [Related]
35. [FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia].
Kawashima N
Rinsho Ketsueki; 2021; 62(8):954-966. PubMed ID: 34497236
[TBL] [Abstract][Full Text] [Related]
36. Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293564
[TBL] [Abstract][Full Text] [Related]
37. FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia.
Tan Y; Xin L; Wang Q; Xu R; Tong X; Chen G; Ma L; Yang F; Jiang H; Zhang N; Wu J; Li X; Guo X; Wang C; Zhou H; Zhou F
Cancer Lett; 2024 Jun; 592():216933. PubMed ID: 38705564
[TBL] [Abstract][Full Text] [Related]
38. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
Zhao J; Song Y; Liu D
Biomark Res; 2019; 7():19. PubMed ID: 31528345
[TBL] [Abstract][Full Text] [Related]
39. Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia.
Kang C; Blair HA
Target Oncol; 2020 Oct; 15(5):681-689. PubMed ID: 32940858
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of
Wu S; Edwards H; Wang D; Liu S; Qiao X; Carter J; Wang Y; Taub JW; Wang G; Ge Y
Cells; 2022 Sep; 11(17):. PubMed ID: 36078163
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]